In Brief: Ciba's Femara
Ciba's Femara: Letrozole tablets (NDA 20-726) for treatment of advanced breast cancer following anti-estrogen therapy in women with naturally or artificially induced post-menopausal status will be reviewed by FDA's Oncologic Drugs Advisory Committee on the morning of Dec. 16. The afternoon session will discuss a new indication for Organon Teknika's TICE Bacille Calmette-Guerin vaccine (PLA 92-0306), intravesical installation for prophylaxis against recurrent papillary carcinoma of the urinary bladder. The meeting will begin at 8:30 a.m. at the Doubletree Hotel in Rockville, Md...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth